MicroRNA-204-5p modulates mitochondrial biogenesis in C2C12 myotubes and associates with oxidative capacity in humans by Houzelle, Alexandre et al.
J Cell Physiol. 2020;1–13. wileyonlinelibrary.com/journal/jcp | 1
Received: 22 August 2019 | Accepted: 15 April 2020
DOI: 10.1002/jcp.29797
OR I G I NA L R E S E A RCH AR T I C L E
MicroRNA‐204‐5p modulates mitochondrial biogenesis in
C2C12 myotubes and associates with oxidative capacity in
humans
Alexandre Houzelle1 | Dennis Dahlmans1 | Emmani B. M. Nascimento1 |
Gert Schaart1 | Johanna A. Jörgensen1 | Esther Moonen‐Kornips1 | Sander Kersten2 |
Xu Wang3,4 | Joris Hoeks1
1Department of Nutrition and Movement
Sciences, NUTRIM School of Nutrition and
Translational Research in Metabolism,
Maastricht University, Maastricht,
The Netherlands
2Division of Human Nutrition, Nutrition,
Metabolism and Genomics Group, Wageningen
University, Wageningen, The Netherlands
3Joint Center for Single Cell Biology, School of
Agriculture and Biology, Shanghai Jiao Tong
University, Shanghai, China
4Laboratory of Integrative Systems Physiology,
Institute of Bioengineering, École
Polytechnique Fédérale de Lausanne,
Lausanne, Switzerland
Correspondence
Joris Hoeks, Department of Nutrition and
Movement Sciences, Maastricht University,
P.O. Box 616, 6200 MD Maastricht,
The Netherlands.
Email: j.hoeks@maastrichtuniversity.nl
Funding information
Netherlands Organization for Scientific
Research (NWO), Grant/Award Number: Vidi
grant 917.14.358; Diabetes Fonds,
Grant/Award Number: Senior Fellowship
2013.82.1639
Abstract
Using an unbiased high‐throughput microRNA (miRNA)‐silencing screen combined
with functional readouts for mitochondrial oxidative capacity in C2C12 myocytes,
we previously identified 19 miRNAs as putative regulators of skeletal muscle mi-
tochondrial metabolism. In the current study, we highlight miRNA‐204‐5p, identified
from this screen, and further studied its role in the regulation of skeletal muscle
mitochondrial function. Following silencing of miRNA‐204‐5p in C2C12 myotubes,
gene and protein expression were assessed using quantitative polymerase chain
reaction, microarray analysis, and western blot analysis, while morphological
changes were studied by confocal microscopy. In addition, miRNA‐204‐5p expression
was quantified in human skeletal muscle biopsies and associated with in vivo mi-
tochondrial oxidative capacity. Transcript levels of PGC‐1α (3.71‐fold; p < .01),
predicted as an miR‐204‐5p target, as well as mitochondrial DNA copy number
(p < .05) and citrate synthase activity (p = .06) were increased upon miRNA‐204‐5p
silencing in C2C12 myotubes. Silencing of miRNA‐204‐5p further resulted in mor-
phological changes, induced gene expression of autophagy marker light chain 3
protein b (LC3B; q = .05), and reduced expression of the mitophagy marker
FUNDC1 (q = .01). Confocal imaging revealed colocalization between the autopha-
gosome marker LC3B and the mitochondrial marker OxPhos upon miRNA‐204‐5p
silencing. Finally, miRNA‐204‐5p was differentially expressed in human subjects
displaying large variation in oxidative capacity and its expression levels associated
with in vivo measures of skeletal muscle mitochondrial function. In summary,
silencing of miRNA‐204‐5p in C2C12 myotubes stimulated mitochondrial biogenesis,
impacted on cellular morphology, and altered expression of markers related to
autophagy and mitophagy. The association between miRNA‐204‐5p and in vivo
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mitochondrial function in human skeletal muscle further identifies miRNA‐204‐5p as
an interesting modulator of skeletal muscle mitochondrial metabolism.
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1 | INTRODUCTION
Mitochondria play critical roles in the regulation of important bio-
logical processes such as energy production (Kasahara & Scorrano,
2014), reactive oxygen species generation (Di Meo, Iossa, & Venditti,
2017), cell growth (Di Meo et al., 2017), and insulin response
(Di Meo et al., 2017). Consequently, the mitochondrial dysfunction
is associated with several disorders, such as cardiovascular disease
(el Azzouzi et al., 2013), cancer (Chourasia, Boland, & Macleod,
2015), neurodegenerative disorders (Pickrell & Youle, 2015), and
metabolic abnormalities such as Type 2 diabetes (Bollinger, Powell,
Houmard, Witczak, & Brault, 2015; Munasinghe et al., 2016). Even in
the absence of disease, maintaining a healthy functioning pool of
mitochondria is essential for cellular/tissue/organismal homeostasis
(Price et al., 2012; Russell, Foletta, Snow, & Wadley, 2014). Sustained
physical activity is considered as one of the most potent interven-
tions to maintain a healthy mitochondrial function and is associated
with several cardiovascular and metabolic health effects. Interest-
ingly, physical activity stimulates mitochondrial function by promot-
ing mitochondrial biogenesis (Montero & Lundby, 2017), but also
by actively inducing the degradation of damaged dysfunctional
mitochondria through mitophagy, the selective degradation of
mitochondria by the autophagic machinery, a process recognized as
essential to maintain mitochondrial function (Lira et al., 2013).
However, the exact molecular mechanisms linking physical exercise
and mitochondrial adaptations in skeletal muscle are incompletely
understood.
In this context, increasing amounts of evidence indicate that
microRNAs (miRNAs) can modulate different aspects of the regula-
tion of mitochondrial function (M. Cheng et al., 2016; Mohamed,
Hajira, Pardo, & Boriek, 2014). MiRNAs are short oligonucleotides of
18–20 nucleotides in length that posttranscriptionally regulate many
biological processes by binding protein‐coding transcripts (Bartel,
2004), adding a new player on an already complex network of gene
regulation. It has been demonstrated that most of the transcriptome
is in fact regulated by miRNAs, including both nuclear‐ and
mitochondria‐encoded messenger RNAs (mRNAs) coding for mi-
tochondrial proteins (Duarte, Palmeira, & Rolo, 2014). Moreover,
miRNAs have been shown to regulate proteins involved in mitochon-
drial maintenance, such as mitochondrial biogenesis (Mohamed
et al., 2014), protein quality control mechanisms (Dahlmans, Houzelle,
Schrauwen, & Hoeks, 2016), mitochondrial dynamics (Dahlmans
et al., 2016), and autophagy (M. Cheng et al., 2016).
Previously, we conducted unbiased hypothesis‐free miRNA‐
silencing screens in C2C12 muscle cells and identified 19 miRNAs as
regulators of skeletal muscle mitochondrial function (Dahlmans
et al., 2017). In a subsequent experiment, we individually silenced these
19 candidate miRNAs in differentiated C2C12 myotubes and quantified
the transcripts of 27 genes involved in different aspects of mitochon-
drial function (Dahlmans et al., 2019). This series of experiments iden-
tified several interesting candidate miRNAs, but here we focus on
miRNA‐204‐5p since silencing of this miRNA clearly increased the ex-
pression of the mRNA encoding the peroxisome proliferator‐activated
receptor‐gamma coactivator‐1α (PGC‐1α) in C2C12 myotubes, both
24 and 48 hr posttransfection. PGC‐1α is a major regulator for mi-
tochondrial biogenesis and oxidative metabolism, plays an important
role in exercise adaptation in muscle, and has been reported to be
downregulated in skeletal muscle of insulin‐resistant and Type 2
diabetic subjects (Patti et al., 2003), whereas its overexpression in mice
resulted in an endurance‐trained phenotype (Lin et al., 2002).
On the basis of these earlier data, the aim of the present study is
to test the hypothesis that miRNA‐204‐5p is involved in the reg-
ulation of skeletal muscle mitochondrial biogenesis and to study its
role in skeletal muscle mitochondrial metabolism in more detail.
2 | MATERIALS AND METHODS
2.1 | Cell culture, reagents, and antibodies
Mouse skeletal muscle C2C12 myoblasts were cultivated in growth
medium consisting of high‐glucose Dulbecco's modified Eagle's
medium (DMEM; Gibco, Carlsbad, CA) supplemented with 10% fetal
bovine serum (Batch Number 1693362), 1% non‐essential amino
acids (Gibco), and 20mM N‐2‐hydroxyethylpiperazine‐N‐2‐ethane
sulfonic acid (HEPES; Gibco). Upon reaching 80–90% confluence,
cells were seeded in 12‐well CellBIND plates (Coring Life Science,
Lowell, CA) or staining slide flasks (Nunc Lab‐Tek Flask on Slide;
Thermo Fisher Scientific, Waltham, MA) at a density of 100,000 cells/
well or 240,000 cells/slide flasks, respectively. Following seeding,
cells were allowed to grow for 24 hr in growth medium. Then, C2C12
myoblasts were differentiated into myotubes for 5 days in high‐
glucose DMEM supplemented with 2% horse serum (Gibco), 1% non‐
essential amino acids (Gibco), and 20mM HEPES (Gibco).
2.2 | In silico analysis
TargetScanMouse, miRanda, and microT‐CDS algorithms were used to
predict the targets of miRNA‐204‐5p. Predicted targets were only
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considered when they were predicted by at least two of the databases.
In addition, all predictions present at least a 7mer site‐matching,
meaning that the entire seed sequence of miRNA‐204‐5p matches the
3′‐ untranslated region (3′‐UTR) sequence of the gene of interest.
2.3 | C2C12 transfection
At Day 5 of differentiation, C2C12 myotubes were transfected with
either a specific miRCURY LNA™ miRNA inhibitor targeting miRNA‐
204‐5p (Exiqon A/S, Vedbæk, Denmark), or a specific locked nucleic
acid (LNA) inhibitor, was used as a negative control. This control LNA
(sequence: TAACACGTCTATACGCCCA) does not target any known
mature miRNA.
Transfection was performed using lipofectamine RNAiMAX
(Invitrogen, Carlsbad), according to the manufacturer's instructions.
Shortly, lipofectamine complexes were stabilized in OptiMEM (Gibco)
for 5min and incubated with the LNAs, diluted to 500 nM in Opti-
MEM, for 20min. Finally, the lipofectamine/LNA complexes were
diluted 1:5 in differentiation media (Dahlmans et al., 2017).
2.4 | RNA preparation and gene expression analysis
in C2C12 cells
Cells were washed with 1ml cold 1X phosphate‐buffered saline (PBS)
and harvested in 700 µl TRIzol reagent (Invitrogen) and kept at
−80oC for subsequent analyses. RNeasy Mini Kits (Qiagen, Venlo,
The Netherlands) were used to extract RNA. RNA quantity and
quality were measured using a nanodrop microvolume spectro-
photometer (ND‐1000; NanoDrop Technologies, Wilmington, DE)
and complementary DNA (cDNA) was synthesized using the High‐
Capacity RNA‐to‐cDNA Kit (Applied Biosystems) according to man-
ufacturer's guidelines. Quantitative polymerase chain reaction
(qPCR) was performed using the SensiMix SYBR Hi‐ROX Kit (Bioline,
London, UK) and specific primer sets (Sigma‐Aldrich, St. Louis, MI) to
quantify the abundance of mRNAs of interest. The qPCR analyses
were performed on the CFX384 Touch™ Real‐Time PCR Detection
System (Bio‐Rad, Hercules, CA).
2.5 | Mitochondrial DNA copy number
quantification
For the determination of mitochondrial DNA (mtDNA) copy number,
DNA was isolated at 24, 36, and 48 hr posttransfection using the
DNeasy Blood & Tissue Kit (Qiagen). DNA was quantified and the
integrity was checked by spectrophotometry using the Nanodrop.
Relative amounts of nuclear and mtDNA were quantified by qPCR, in
which nuclear DNA was represented by the UCP2 gene and mtDNA
by the COX2 gene. qPCR was performed on the ABI Prism 7900HT
Real‐Time PCR System (Applied Biosystems, Foster City, CA).
MtDNA copy number was calculated using the ΔCt method.
2.6 | Luciferase reporter assay
C2C12 cells were cultured in DMEM (4.5 g/L D‐glucose) supple-
mented with 10% fetal bovine serum, 2% HEPES, and 1% minimum
essential medium non‐essential amino acids solution and seeded in
24‐well plates at a density of 50,000 cells/well. The next day, cells
were transfected with hsa‐miRNA‐204‐5p or Neg control #1
(Ambion; Life Technologies, Waltham) precursor molecules and
cotransfected with the LightSwitch_PPARGC1A_3′UTR vector
(Active Motif, Carlsbad) using Lipofectamine 2000 (Invitrogen,
Waltham). After 24 hr, the luciferase activity was determined
using the LightSwitch Luciferase Assay Reagent (SwitchGear
Genomics, Carlsbad) according to the manufacturer's instructions
using a GLOMAX Microplate Luminometer (Promega Corporation,
Madison, WI).
2.7 | Microarray analysis
Purified RNA was labeled with the Ambion WT Expression Kit
(Carlsbad) and hybridized to an Affymetrix Mouse Gene 1.1 ST
array plate (Affymetrix, Santa Clara, CA). Hybridization, washing,
and scanning were carried out on an Affymetrix GeneTitan plat-
form according to the manufacturer's instructions. Normalized
expression estimates were obtained from the raw intensity values
applying the robust multiarray analysis preprocessing algorithm
available in the Bioconductor library affyPLM with default settings
(Bolstad, Irizarry, Astrand, & Speed, 2003; Irizarry et al., 2003).
Probe sets were defined according to Dai et al. (2005). In this
method, probes are assigned to Entrez IDs as a unique gene
identifier. In this study, probes were reorganized based on the
Entrez Gene database, build 37, Version 1 (remapped CDF v22).
q values were calculated using an intensity‐based moderated
T‐statistic (Sartor et al., 2006). Genes were defined as significantly
changed when q < .05.
2.8 | Protein extraction and western blot analysis in
C2C12 muscle cells
Cells were washed with 1ml cold 1X PBS and scraped in 150 µl Bio‐
Plex cell lysis buffer (Bio‐Rad), and processed according to the
manufacturer's instruction. Protein loading for each sample was first
determined using InstantBlue Coomassie (Expedeon, San Diego, CA).
Equal amounts of protein were loaded in precast sodium dodecyl
sulfate‐polyacrylamide gel electrophoresis (Mini TGX AnyKD or
Criterion TGX AnykD; Bio‐Rad). Next, LC3B‐I and LC3B‐II were de-
tected using an antibody directed against LC3B, diluted 1:1000
(L7543; Sigma‐Aldrich). Furthermore, an antibody directed against
β‐actin was diluted 1:25,000 (A5316; Sigma‐Aldrich), and was used
as a loading control. Finally, membranes were quantified at the
appropriate wavelengths using an Odyssey CLx Imaging System
(Li‐COR, Lincoln, NE).
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2.9 | Live cell imaging in C2C12 cells
C2C12 myoblasts were seeded in 12‐well CellBIND plates (Corning)
at 100,000 cells/well and allowed to settle overnight in the growth
medium. Then, the medium was replaced to differentiation medium
and cells were transfected as previously described. Continuous cell
monitoring was performed for 10 days using the IncuCyte ZOOM
(Essen Bioscience, Ltd., Hertfordshire, UK). The differentiation med-
ium was replaced every 48 hr to maintain the cells for the duration of
the experiments.
2.10 | Immunocytochemistry in C2C12 cells
C2C12 myoblasts were seeded in slide flasks (Nunc Lab‐Tek Flask on
Slide; Thermo Fisher Scientific) at 240,000 cells/flask and differ-
entiated for 5 days. Then, myotubes were transfected and fixated
48 hr posttransfection. To fix the cells, myotubes were washed three
times in PBS and incubated for 1 hr in 3.7% formaldehyde at room
temperature. Finally, fixed myotubes were washed three times in PBS
and stored in PBS at 4°C until immunocytochemistry was performed.
Before staining, slides were rinsed for 5min in PBS and directly in-
cubated with primary antibodies diluted in 0.05% Tween‐20 in PBS.
Mitochondria were stained by an anti‐OxPhos antibody cocktail
(MS604; MitoSciences, Eugene, OR), targeting structural subunits of
all OxPhos complexes. Autophagosomes were visualized by using an
anti‐LC3B antibody (L7543; Sigma‐Aldrich). Image acquisition was
performed using a Nikon Eclipse E800 fluorescent microscope
equipped with ×40 oil immersion objective (Nikon Instruments,
Amsterdam, The Netherlands) or a Leica TCS SP8 confocal micro-
scope equipped with a ×63 1.40NA oil immersion objective (Leica,
Amsterdam). The confocal images were processed using deconvolu-
tion software (Huygens Professional; Scientific Volume Imaging B.V.,
Hilversum, The Netherlands).
2.11 | Subject selection and human muscle biopsies
collection
The subjects included in this study participated in previous studies
(Phielix, Meex, Moonen‐Kornips, Hesselink, & Schrauwen, 2010;
Phielix et al., 2012; Vosselman et al., 2015; van de Weijer et al., 2015)
that were approved by the institutional medical ethics committee,
registered at ClinicalTrials.gov (NCT00943059 and NCT01298375)
and in the Dutch trial register (NL1888) and for which all participants
provided their written informed consent in accordance with the de-
claration of Helsinki. From these studies, we selected four groups of
male, weight‐stable individuals for the analysis of miRNA‐204‐5p
expression in skeletal muscle and its relation to parameters for
in vivo oxidative capacity. These four groups included: (a) Type 2
diabetic patients (n = 12); (b) overweight/obese nondiabetic subjects
(n = 12); (c) young lean individuals (n = 12), and (d) young endurance‐
trained athletes (n = 12). The primary selection was based on the
availability of muscle material and the presence of reliable data for in
vivo oxidative capacity (maximal aerobic capacity [VO2 max] and
phosphocreatine [PCr] recovery rate). Second, subjects were also
selected with the intention to create age‐ and body mass index‐
matched groups (i.e., Group 1 vs. Group 2 and Group 3 vs. Group 4).
All Type 2 diabetes patients were on metformin treatment and
the use of statins was permitted. Obese nondiabetic individuals were
considered healthy, that is, they did not use medication, did not
present any pathology (hypertension, cardiovascular disorders, and
liver dysfunction), and did not have any first‐degree relatives with
Type 2 diabetes.
Lean sedentary (LS) subjects were included if their VO2 max was
below 45ml−1·min−1·kg and did not participate in more than 1 hr of
organized exercise per week for the previous 2 years. Endurance‐
trained athletes were enrolled in the study if their VO2 max was
higher than 55ml−1·min−1·kg and if they participated in endurance
training at least three times per week for the last 2 years.
All biopsies were collected after an overnight (≥10 hr) fast and
before any intervention. Subjects were instructed to avoid (stren-
uous) physical exercise in the 3‐day period preceding the muscle
biopsy.
2.12 | Subject characterization
All subjects included in this study were thoroughly phenotyped in
term of body composition and aerobic capacity. Body composition
was determined either via dual X‐ray absorptiometry (Discovery A;
Hologic, Bedford, MA) or hydrostatic weighing (Siri, 1993). Maximal
aerobic capacity was determined through an incremental cycling test
until exhaustion, as described previously (Kuipers, Verstappen,
Keizer, Geurten, & van Kranenburg, 1985). In vivo mitochondrial func-
tion was assessed via quantification of PCr resynthesis rates using a
31P magnetic resonance spectrometry approach on a 3 T whole‐body
scanner (Achieve 3T‐X; Philips Healthcare, The Netherlands), as
previously described (Lindeboom et al., 2014).
2.13 | MiRNA quantitative PCR in muscle biopsies
A 10–15mg piece of frozen muscle tissue was homogenized in 700 µl
of TRIzol with an Ultra‐Turrax (IKA, Staufen, Germany) for 1min at
17,000 rpm. RNA isolation was then performed using a miRNeasy
Mini Kit (Qiagen) according to the manufacturer's instructions. The
yield was improved by reloading the final eluate onto the column
membrane twice. RNA concentrations were measured using a mi-
crovolume spectrophotometer (Nanodrop), whereas RNA quality was
determined using a Bioanalyzer System (Agilent Technologies, Santa
Clara, CA). Then, cDNA synthesis was performed using the Universal
cDNA Synthesis Kit II (Exiqon) according to the manufacturer's
protocol. Finally, cDNA samples were analyzed using predesigned
384‐well Pick‐&‐Mix microRNA PCR Panel plates (Exiqon), according
to the manufacturer's guidelines using a CFX384 Touch Real‐time
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PCR Detection System (Bio‐Rad). Relative miRNA expression levels
were determined using the ΔΔCt method. Synthetic UniSP6 spike‐in
control was used to monitor the cDNA synthesis reaction, that is, as a
positive control of the reverse transcription. Furthermore, an inter-
polate calibrator was added to all qPCR plates to uniformly normalize
Ct values across all the experiments.
2.14 | Statistics analysis
All results are expressed as means ± standard deviation. Each set of
in vitro data presented in this study is the result of three in-
dependently executed experiments, each of which includes three
technical replicates (unless indicated otherwise in the figure legend).
Comparisons between in vitro conditions were performed by un-
paired two‐tailed Student's t test. Comparisons over time were
performed by two‐way analysis of variance (ANOVA). p < .05 was
considered statistically significant.
Differences between the various human subject groups
were assessed via one‐way ANOVA with Tukey's multiple com-
parisons test. Pearson correlation analysis was used to correlate
miRNA‐204‐5p expression in skeletal muscle to in vivo para-
meters of oxidative capacity.
3 | RESULTS
3.1 | miRNA‐204‐5p silencing in C2C12 myotubes
increases PGC‐1α gene expression
We previously silenced 19 individual candidate miRNAs, identified in
a large miRNA‐silencing screen (Dahlmans et al., 2017), and subse-
quently measured 27 genes involved in mitochondrial function
(Dahlmans et al., 2019). Interestingly, the silencing of miRNA‐204‐5p
showed a pronounced induction of the expression of PGC‐1α, a well‐
known regulator of mitochondrial biogenesis, both when silenced for
24 (2.43‐fold; p < .05) and 48 hr (3.71‐fold; p < .01; Figure 1). Sub-
sequent in silico analysis by TargetScan and miRanda revealed a
specific sequence in the 3′‐UTR of PGC‐1α as a predicted target to
the seed region of miRNA‐204‐5p (Figure 1a). In addition, both
miRNA‐204‐5p and the binding site in the 3′‐UTR of PGC‐1α were
conserved over many different invertebrates as well as vertebrate
species including humans, but not worm (Figure 1a). Moreover,
activity assays using a luciferase reporter construct harboring the
PGC‐1α 3′‐UTR revealed that increasing concentrations of pre‐
miRNA‐204‐5p significantly and dose‐dependently reduced the
luciferase reporter signal, indicating a functional interaction between
miRNA‐204‐5p and the 3′‐UTR of PGC‐1α (Figure 1b).
F IGURE 1 miRNA‐204‐5p silencing induces mitochondrial biogenesis through PGC‐1α induction. (a) Representation of the binding between
the 3′‐UTR of PGC‐1α mRNA and miRNA‐204‐5p in different species. (b) Activity assay of a luciferase reporter constructs harboring the
PGC‐1α 3′‐UTR after transfection with a synthetic precursor for miRNA‐204‐5p. Data shown are the result of three independently executed
duplicate experiments. (c) Relative PGC‐1α gene expression upon miRNA‐204‐5p silencing compared to Negative Control A (NegA), 24 and
48 hr posttransfection in C2C12 myotubes. (d) Citrate synthase activity following 24 and 48 hr transfection of anti‐miRNA‐204‐5p versus NegA
in C2C12 myotubes. (d) Mitochondrial DNA copy number and nuclear DNA upon miRNA‐204‐5p silencing versus NegA. *p < .05 and **p < .01
(n = 3). 3′‐UTR, 3′‐untranslated region; miRNA, microRNA; mRNA, messenger RNA; PGC‐1α, peroxisome proliferator‐activated receptor‐gamma
coactivator‐1α
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To address the consequences of the increase in PGC‐1α ex-
pression (Figure 1c), we next assessed citrate synthase activity as
well as mtDNA copy number as markers for mitochondrial density. In
line with the elevated PGC‐1α expression, citrate synthase activity
(Figure 1d) showed a strong tendency to be increased after 24 hr
miRNA‐204‐5p silencing (25% increase; p = .06), whereas the differ-
ence did not reach statistical significance at 48 hr. MtDNA copy
number was significantly increased (46% increase; p < .05) 36 hr
posttransfection, but not after 24 or 48 hr miRNA‐204‐5p silencing
(Figure 1e). Together, these results indicate a (transient) increase in
mitochondrial content upon miRNA‐204‐5p silencing, which promp-
ted us to further analyze the role of miRNA‐204‐5p in regulating
mitochondrial metabolism.
3.2 | miRNA‐204‐5p silencing induces
morphological aberrations in C2C12 myotubes
To investigate if the silencing of miRNA‐204‐5p also resulted in
morphological changes that could reveal enhanced mitochondrial
density, we next studied the effect of miRNA‐204‐5p silencing on
C2C12 myotube development and continuously monitored the
transfected C2C12 myotubes for 72 hr after transfection. Interest-
ingly, myotubes transfected with anti‐miRNA‐204‐5p displayed
morphological changes that were most apparent 48 hr post-
transfection. Thus, whereas nontransfected and Negative Control A
transfected C2C12 myotubes displayed a normal morphology and
similar appearance as control cells (Figure 2a–e) 48 hr post-
transfection, (i.e., at Day 7 of differentiation) myotubes transfected
with anti‐miRNA‐204‐5p showed large round anomalous structures
within the myotubes (Figure 2f–j).
Strikingly, when undifferentiated C2C12 muscle cells were
transfected with anti‐miRNA‐204‐5p and subsequently underwent
differentiation, the aberrant structures did not appear before Day 5
of differentiation (Figure 3). In other words, C2C12 muscle cells
transfected with Negative Control A or anti‐miRNA‐204‐5p in the
myoblasts stage, displayed similar and normal morphology during the
first 4 days of subsequent differentiation (Figure 3). Again, although
the morphological abnormalities started to appear at Day 5 of dif-
ferentiation, the irregular cellular morphology was most apparent at
Day 7 of differentiation (Figure 3h), comparable to the changes seen
after silencing miRNA‐204‐5p in already differentiated C2C12
myotubes.
3.3 | Silencing of miRNA‐204‐5p affects markers for
autophagy/mitophagy
We next hypothesized that the abnormal phenotype of the C2C12
myotubes upon miRNA‐204‐5p silencing could possibly be explained
by increased autophagic activity, especially since microtubule‐
associated protein 1A/1B‐LC3B, a major player in autophagosome
formation, is another predicted target (Figure 4a) of miRNA‐204‐5p
as shown previously in renal cell carcinoma (Mikhaylova et al., 2012).
To study whether the morphological abnormalities that we observed
in the C2C12 myotubes could be related to autophagy, we first
performed a microarray analysis 24 hr posttransfection and focused
on the expression of several autophagy‐related genes. Indeed, the
miRNA‐204‐5p predicted target LC3B, as well as autophagosome and
lysosome fuser VAMP8 and lysosomal cysteine protease inhibitor
cystatin B (CSTB), were significantly increased following anti‐miRNA‐
204‐5p treatment (Figure 4b). A similar expression pattern was
F IGURE 2 Silencing miRNA‐204‐5p induces the development of an aberrant morphology in C2C12 myotubes. C2C12 myoblasts were
differentiated for 5 days prior transfection with either Negative Control A or an LNA targeting miRNA‐204‐5p, and were subsequently observed
for 72 hr. The development of the aberrant phenotype was consistently observed 48 hr posttransfection. (a–e) C2C12 myotubes transfected
with of Negative Control A. (f–j) C2C12 myotubes transfected with an LNA directed against miRNA‐204‐5p. Panels are bright‐field micrographs.
Red arrows indicate C2C12 myotubes with atypical morphology. Scale bar = 400 μm (n = 3). LNA, locked nucleic acid; miRNA, microRNA
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observed for the autophagy markers GABARAPL1 and SQSTM1
(Figure 4b), although these changes did not reach statistical sig-
nificance. Interestingly, however, mitophagy markers PARK2, BNIP3,
BNIP3L, and FUNDC1 appeared to be decreased after miRNA‐204‐5p
lowering, although this was only statistically significant for FUNDC1
(Figure 4b).
Next, to investigate if the induction of autophagy markers was
translated to the protein level, we quantified the abundance of LC3B‐I
and LC3B‐II protein 12, 24, 36, 48, and 72 hr posttransfection.
Despite the apparent induction of several autophagy‐related genes
and the aberrant phenotype of the cells, 48 hr posttransfection with
anti‐miRNA‐204‐5p (as displayed in Figure 2), we could not detect
changes in protein abundance of LC3B‐I or LC3B‐II after silencing
miRNA‐204‐5p (Figure 4c). However, since we previously demon-
strated that the morphological phenotype only occurs in fully dif-
ferentiated C2C12 myotubes, and not myoblasts, changes in LC3B
abundance might have been masked by the presence of un-
differentiated myoblasts in our cell cultures. To circumvent this
problem, we finally performed immunocytochemistry with an anti-
body against LC3B and investigated LC3B in miRNA‐204‐5p silenced
C2C12 myotubes. Indeed, while C2C12 myotubes transfected with
Negative Control A displayed a diffuse, ubiquitous LC3B expression
(Figure 5a), miRNA‐204‐5p silencing induced a typical punctuated
staining of LC3B, 48 hr posttransfection (Figure 5b). The observed
LC3B staining was similar to the pattern observed in C2C12 myo-
tubes transfected with Negative Control A and subsequently treated
with chloroquine, which is known to induce the accumulation of
LC3B‐positive autophagosomes by inhibiting their clearance
(Figure 5c). Finally, we performed double staining for LC3B
and OxPhos, as a marker for mitochondria, in C2C12 myotubes,
48 hr posttransfection with either Negative Control A or anti‐
miRNA‐204‐5p. Interestingly, whereas OxPhos displayed a diffuse
homogenous staining in the Negative Control A transfected
cells, we observed a punctuated OxPhos localization in the anti‐
miRNA‐204‐5p transfected cells that were similar to the LC3B
staining pattern. Furthermore, the merged images of OxPhos and
LC3B demonstrated the colocalization of both mitochondria and
the autophagosomal marker LC3B (Figure 6).
3.4 | miRNA‐204‐5p expression correlates to in
vivo mitochondrial function in human skeletal muscle
To test whether these findings are relevant in human physiology, we
then selected (from previous human clinical trials performed in our
facilities [Phielix et al., 2010; Phielix et al., 2012; van de Weijer
et al., 2015; Vosselman et al., 2015]) four subject groups known to be
characterized by different mitochondrial abundance and oxidative
capacity, including Type 2 diabetes patients (Type 2 diabetes mellitus
[T2DM]), obese nondiabetic subjects (O), LS individuals, and
endurance‐trained athletes (A) and investigated miRNA‐204‐5p ex-
pression in skeletal muscle biopsies. Also, VO2 max and PCr recovery
rates were determined, although the latter could not be assessed in
the entire cohort (n = 38). The characteristics of the subjects included
for the current study are displayed in Table 1. VO2 max and PCr
recovery were highest in endurance‐trained athletes and lowest in
patients with T2DM (Table 1).
Interestingly, the expression of miRNA‐204‐5p in skeletal muscle
was different between the Type 2 diabetic individuals and
endurance‐trained athletes as assessed by one‐way ANOVA with
Tukey's post hoc correction for multiple testing. Thus, the expression
of miRNA‐204‐5p was 1.85‐fold (p = .008) higher in Type 2 diabetes
patients with a low mitochondrial oxidative capacity when compared
to the endurance‐trained athletes with an optimal mitochondrial
F IGURE 3 miRNA‐204‐5p silencing only affects fully differentiated C2C12 myotubes. Undifferentiated C2C12 myoblasts were transfected
with either Negative Control A or an LNA targeting miRNA‐204‐5p, and were subsequently observed for 7 days. (a–d) Negative Control A. (e–h)
Transfection of an LNA against miRNA‐204‐5p. Red arrows indicate C2C12 myotubes with atypical morphology. Panels are bright‐field
micrographs (n = 2). Scale bar = 400 μm. LNA, locked nucleic acid; miRNA, microRNA
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F IGURE 4 miRNA‐204‐5p silencing does not increase LC3B‐I or LC3B‐II protein abundance. (a) Representation of the binding between the
3′‐UTR of LC3B (MAP1LC3B) mRNA and miRNA‐204‐5p across different species. (b) Gene expression analysis (microarray analysis) following
anti‐miRNA‐204‐5p (24 hr) in differentiated C2C12 myotubes. *q < .05 (FDR adjusted q‐value intensity‐based moderated T‐statistic, n = 3).
(c) LC3B‐I and LC3B‐II protein levels were quantified using western blot analysis 12, 24, 36, 48, and 72 hr posttransfection with either Negative
Control A or anti‐miRNA‐204‐5p. In addition, transfected cells were compared to chloroquine treated C2C12 myotubes as a positive control
(n = 3). 3′‐UTR, 3′‐untranslated region; FDR, false discovery rate; LC3B, light chain 3 protein b; miRNA, microRNA; mRNA, messenger RNA;
NC, negative control
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oxidative capacity (Figure 7a). In addition, miRNA‐204‐5p expression
negatively correlated with VO2 max (r = −.38, p = .011; Figure 7b) and
positively correlated with PCr recovery rates (r = .37, p = .023;
Figure 7c). Collectively, these collective results indicate that low
miRNA‐204‐5p expression is associated with high in vivo mitochon-
drial oxidative capacity in humans, that is, a high VO2 max and a fast
PCr recovery.
4 | DISCUSSION
We previously conducted a high‐throughput hypothesis‐free
miRNA‐silencing screen in C2C12 muscle cells and identified several
miRNAs as potential regulators of mitochondrial function (Dahlmans
et al., 2017). Here, we further investigated one of these miRNAs and
observed that miRNA‐204‐5p silencing in C2C12 myotubes resulted
in the induction of PGC‐1α gene expression and mitochondrial bio-
genesis and that miRNA‐204‐5p expression in human muscle nega-
tively correlated to oxidative capacity.
In the present study, miRNA‐204‐5p silencing induced
PGC‐1α, a transcriptional cofactor pivotal in the regulation of
mitochondrial biogenesis, which prompted us to study the role of
miRNA‐204‐5p in the regulation of mitochondrial metabolism in
more detail. Interestingly, the increase in PGC‐1α gene expression
was accompanied by an increase in citrate synthase activity and
mtDNA copy number, known markers of mitochondrial content.
We could also show a direct interaction between miRNA‐204‐5p
and the 3′‐UTR of PGC‐1α. To the best of our knowledge, this is
the first study to directly link miRNA‐204‐5p to mitochondrial
biogenesis in skeletal muscle, whereas most studies regarding
F IGURE 5 miRNA‐204‐5p silencing leads to the activation of LC3B and the accumulation of autophagosomes in C2C12 myotubes.
C2C12 myoblasts were differentiated for 5 days and transfection with either Negative Control A (a) or an LNA targeting miRNA‐204‐5p
(b) for 48 hr. Immunocytochemistry targeting the autophagosome marker LC3B (green) or nuclei (blue) was performed. (c) Twenty‐four hours
chloroquine incubation (1 μg/ml) was used as a positive control for autophagosome accumulation (n = 4). LC3B, light chain 3 protein b;
LNA, locked nucleic acid; miRNA, microRNA
F IGURE 6 miRNA‐204‐5p silencing targets mitochondria for autophagy. C2C12 myotubes silenced with an anti‐miRNA‐204‐5p displayed
colocalization of the autophagosome marker LC3B (green) and the mitochondrial marker OxPhos (red), indicating that mitochondria are
targeted for autophagy (mitophagy). Scale bar = 25 μm (n = 3). DAPI, 4′,6‐diamidino‐2‐phenylindole; LC3B, light chain 3 protein b; miRNA,
microRNA
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miRNA‐204‐5p have been focusing on its roles in cancer. In the
context of gastric cancer, however, miRNA‐204‐5p has also been
reported to regulate SIRT1 expression, a known metabolic reg-
ulator, and upstream target of PGC‐1α (Canto & Auwerx, 2009),
indicating that miRNA‐204‐5p may also regulate mitochondrial
function in an indirect fashion.
Intriguingly, the silencing of miRNA‐204‐5p also led to the con-
sistent development of an aberrant morphological phenotype. In this
context, previous studies in renal carcinoma cells have demonstrated
that miRNA‐204‐5p is able to regulate autophagy by directly tar-
geting LC3B's broadly conserved 3′‐UTR (Mikhaylova et al., 2012;
Xiao et al., 2011). Therefore, we studied several markers of
TABLE 1 Subject characteristics
T2DM# Obese$
Lean
Sedentary* Athletes&
n 11 12 11 11
Age, years 58.6 ± 4.0 56.7 ± 7.2 22.2 ± 2.7 25.3 ± 4.5
***, &&& ***, &&& ###, $$$ ###, $$$
Weight, kg 100.2 ± 12.6 94.1 ± 13.8 73.7 ± 7.1 70.6 ± 7.7
***, &&& ***, &&& ###, $$$ ###, $$$
Height, m 1.77 ± 0.08 1.74 ± 0.07 1.83 ± 0.05 1.83 ± 0.07
*, & $ $
BMI, kg/m2 32.4 ± 3.7 31.0 ± 3.7 22.1 ± 1.8 21.0 ± 1.5
***, &&& ***, &&& ###, $$$ ###, $$$
Fat (%) 33.8 ± 4.9 34.7 ± 7.0 18.1 ± 3.7 12.7 ± 2.1
***, &&& ***, &&& ###, $$$ ###, $$$
VO2 max, ml
−1·min−1·kg
(lean mass)
37.6 ± 4.5 42.8 ± 6.9 50.4 ± 3.4 68.9 ± 4.6
***, &&& **, &&& ###, $$, &&& ###, $$$, ***
PCr recovery, sa 26.7 ± 6.1 21.3 ± 4.4 20.8 ± 3.9 15.9 ± 5.1
&&& ###
Note: Age, weight, height, body mass index (BMI), body composition, and in vivo (mitochondrial)
oxidative capacity in Type 2 diabetic patients (T2DM), nondiabetic overweight/obese individuals, lean
sedentary individuals, and endurance‐trained athletes. Values presented are mean ± SD. Significance
is indicated with #, $, *, and & representing changes compared to T2DM, obese, lean sedentary, and
athletic subjects, respectively, and with 1, 2, and 3 symbols representing p < .05, p < .01, and p < .001,
respectively. Statistical significances are based on one‐way ANOVA with Tukey's post hoc test.
Abbreviations: ANOVA, analysis of variance; PCr, phosphocreatine; SD, standard deviation; T2DM,
Type 2 diabetes mellitus; VO2 max, maximal aerobic capacity.
aFor PCr recovery, group size for the lean sedentary subjects and the endurance‐trained athletes are
n = 6 and n = 9, respectively.
F IGURE 7 miRNA‐204‐5p levels in human biopsies correlates with oxidative capacity in vivo. (a) miRNA‐204‐5p expression was assessed in
skeletal muscle (vastus lateralis) biopsies from Type 2 diabetic (T2DM), obese (O), lean sedentary (LS), and athletic (A) subjects. *p < .05 one‐way
ANOVA with Tukey's post hoc testing for multiple comparisons. Pearson's correlation between miRNA‐204‐5p expression and (b) VO2 max
(normalized for lean body mass) and between miRNA‐204‐5p expression and (c) PCr recovery rate, a measure for in vivo mitochondrial capacity.
ANOVA, analysis of variance; miRNA, microRNA; PCr, phosphocreatine; T2DM, Type 2 diabetes mellitu; VO2 max, maximal aerobic capacity
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autophagy and found that miRNA‐204‐5p silencing increased LC3B
gene—but not protein—expression levels and resulted in an LC3B
staining pattern suggestive for autophagosome formation. Since the
autophagosomal marker LC3B also colocalized with mitochondria
upon miRNA‐204‐5p silencing, this possibly reflects the autophagic
clearance of mitochondria, a process called mitophagy. Arguing
against this notion, gene expression of the mitophagy marker
FUNDC1 was significantly reduced. Furthermore, since we did not
directly assess autophagic flux, our data do not exclude the possibi-
lity that anti‐miRNA‐204‐5p treatment may inhibit—rather than
activate—autophagy by blocking lysosome and autophagosome fu-
sion, ultimately resulting in failure to form autophagosomes. In fact,
we found some support for this possibility since gene expression of
autophagosome and lysosome fuser VAMP8 and proteinases release
protector from lysosomes CSTB appeared to be increased in anti‐
miRNA‐204‐5p treated C2C12 myotubes. Thus, we found support for
the involvement of miRNA‐204‐5p in autophagy although its reg-
ulatory function in this process requires further study.
In addition, the phenotype of the cells may have been affected by
changes in the differentiation process, as miRNA‐204‐5p has been
shown to inhibit C2C12 myoblast differentiation, most likely through
inhibition of MEFC2 an ERRγ (X. Cheng et al., 2018). Interestingly,
miRNA‐204‐5p expression was also decreased during C2C12 myo-
tube differentiation (X. Cheng et al., 2018), whereas the oxidative
phenotype of C2C12 myotubes has been shown to increase during
myotube differentiation (Remels et al., 2010). This enhanced capacity
for oxidative phosphorylation requires extensive remodeling of the
mitochondrial network and it has been shown that autophagy/mito-
phagy is required for this remodeling, which is also integratively
linked to C2C12 myotube differentiation (Sin et al., 2016). Taken
together, these findings indicate that miRNA‐204‐5p may play a role
in the interplay of mitochondrial biogenesis, autophagy/mitophagy,
and myogenic differentiation.
Interestingly, clearing dysfunctional mitochondria through mi-
tophagy appears important for maintaining metabolic health, as this
process has been shown to be dysregulated in obese (Bollinger
et al., 2015) and Type 2 diabetic subjects (Munasinghe et al., 2016),
and has shown to be important for exercise‐induced adaptations (He
et al., 2012; Lira et al., 2013; Moller et al., 2015; Saleem, Carter, &
Hood, 2014; Vainshtein, Tryon, Pauly, & Hood, 2015). Furthermore, it
has been demonstrated that PGC‐1α also plays a role in the regula-
tion of mitophagy (Vainshtein et al., 2015). Thus, acute exercise in-
creased the expression of mitophagy‐related genes in wild‐type, but
not in PGC‐1α knock‐out mice. In addition, mitochondria were tar-
geted for mitophagy post‐exercise in wild‐type mice, whereas this
response was diminished in PGC‐1α knock‐out mice (Vainshtein
et al., 2015), indicating a dual role for PGC‐1α in both mitochondrial
biogenesis and mitophagy. The observed increases in PGC‐1α gene
expression, in combination with the observed colocalization of mi-
tochondria with autophagosomes, could be suggestive of increased
mitochondrial turnover, although this could not be directly tested in
the current study.
To address the human relevance of our findings, we also de-
termined the expression of miRNA‐204‐5p in human skeletal muscle
biopsies from individuals ranging widely in mitochondrial oxidative
capacity. We observed that individuals with a high mitochondrial
oxidative capacity are characterized by a low expression of miRNA‐
204‐5p. It should be noted though that age may be a confounding
factor in this correlation given the significant age difference between
certain subject groups (Table 1). Nonetheless, exercise training has
been shown to induce PGC‐1α and mitochondrial biogenesis as well
as markers for autophagy and mitophagy in human skeletal muscle
(Balan et al., 2019; Brandt, Gunnarsson, Bangsbo, & Pilegaard, 2018;
Egan, O'Connor, Zierath, & O'Gorman, 2013; Popov, Lysenko,
Makhnovskii, Kurochkina, & Vinogradova, 2017). Together with our
results in C2C12 cells upon silencing of miRNA‐204‐5p, one may
postulate that low levels of miRNA‐204‐5p simultaneously induce
mitochondrial biogenesis as well as mitochondrial degradation and
that this enhanced mitochondrial “turnover” is linked to oxidative
capacity in human skeletal muscle.
In summary, we here demonstrated that the silencing of miRNA‐
204‐5p in C2C12 myotubes enhanced mitochondrial biogenesis, via
regulation of PGC‐1α. In addition, the anti‐miRNA‐204‐5p treatment
also substantially affected the morphology of differentiated C2C12
myotubes and altered several markers related to autophagy and
mitophagy. Finally, in humans, low expression of miRNA‐204‐5p in
skeletal muscle was associated with high oxidative capacity. In con-
clusion, this study identifies miRNA‐204‐5p as an interesting mod-
ulator of mitochondrial function in human skeletal muscle.
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